{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T10:45:14Z","timestamp":1749465914594},"reference-count":214,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[1984,9,1]],"date-time":"1984-09-01T00:00:00Z","timestamp":462844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[1984,9,1]],"date-time":"1984-09-01T00:00:00Z","timestamp":462844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med. Oncol. &amp; Tumor Pharmacother."],"published-print":{"date-parts":[[1984,9]]},"DOI":"10.1007\/bf02934139","type":"journal-article","created":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T18:21:13Z","timestamp":1631902873000},"page":"169-192","source":"Crossref","is-referenced-by-count":11,"title":["Chemotherapy of breast cancer"],"prefix":"10.1007","volume":"1","author":[{"given":"Lawrence S.","family":"Perlow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James F.","family":"Holland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF02934139_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3322\/canjclin.33.1.9","volume":"33","author":"E Silverberg","year":"1983","unstructured":"Silverberg E: Cancer statistics, 1983.Ca-A Cancer J for clin\n                           33, 9 (1983).","journal-title":"Ca-A Cancer J for clin"},{"key":"BF02934139_CR2","unstructured":"Perlow L, Holland J F: Chemotherapy of breast cancer, in Deppe G. (ed):Chemotherapy of Gynecologic Cancer. New York, Alan A. Liss, (in press)."},{"key":"BF02934139_CR3","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1002\/1097-0142(19801215)46:12+<2884::AID-CNCR2820461429>3.0.CO;2-U","volume":"40","author":"C Osborne","year":"1980","unstructured":"Osborne C, Yochmowitz M, Knight W, McGuire W: The value of estrogen and progesterone receptors in the treatment of breast cancer.Cancer 40 (Suppl), 2884 (1980).","journal-title":"Cancer"},{"key":"BF02934139_CR4","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1002\/1097-0142(19801215)46:12+<2829::AID-CNCR2820461419>3.0.CO;2-M","volume":"46","author":"M Lippman","year":"1980","unstructured":"Lippman M, Allegra J: Quantitative estrogen receptor analyses: the response to endocrine and cytotoxic chemotherapy in human breast cancer and the disease-free interval.Cancer\n                           46 (Suppl), 2829 (1980).","journal-title":"Cancer"},{"key":"BF02934139_CR5","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1002\/1097-0142(19801215)46:12+<2779::AID-CNCR2820461407>3.0.CO;2-R","volume":"46","author":"T Dao","year":"1980","unstructured":"Dao T, Nemoto T: Steroid receptors and response to endocrine ablations in women with metastatic cancer of the breast.Cancer\n                           46 (Suppl), 2779 (1980).","journal-title":"Cancer"},{"key":"BF02934139_CR6","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1002\/1097-0142(19801215)46:12+<2838::AID-CNCR2820461421>3.0.CO;2-A","volume":"46","author":"A Manni","year":"1980","unstructured":"Manni A, Arafah B, Pearson O: Estrogen and progesterone receptors in the prediction of response of breast cancer to endocrine therapy.Cancer\n                           46 (Suppl), 2838 (1980).","journal-title":"Cancer"},{"key":"BF02934139_CR7","first-page":"89","volume":"1","author":"P Johnson","year":"1982","unstructured":"Johnson P, Bonomi P, Anderson K, Walter J, Rossof A, Economou S: Megestrol acetate (MA) in advanced breast cancer: response rate related to estrogen receptor (ER) and progesterone receptor (PR) levels.Proc ASCO\n                           1, 89 (1982).","journal-title":"Proc ASCO"},{"key":"BF02934139_CR8","doi-asserted-by":"publisher","first-page":"2922","DOI":"10.1002\/1097-0142(19801215)46:12+<2922::AID-CNCR2820461435>3.0.CO;2-D","volume":"46","author":"R Rubens","year":"1980","unstructured":"Rubens R, Hayward J: Estrogen receptors and response to endocrine therapy and cytotoxic chemotherapy in advanced breast cancer.Cancer\n                           46 (Suppl), 2922 (1980).","journal-title":"Cancer"},{"key":"BF02934139_CR9","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1002\/1097-0142(19801215)46:12+<2961::AID-CNCR2820461444>3.0.CO;2-E","volume":"46","author":"P Young","year":"1980","unstructured":"Young P, Ehrlich C, Einhorn L: Relationship between steroid receptors and response to endocrine therapy and cytotoxic chemotherapy in metastatic breast cancer.Cancer\n                           46 (Suppl), 2961 (1980).","journal-title":"Cancer"},{"key":"BF02934139_CR10","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1002\/1097-0142(19801215)46:12+<2889::AID-CNCR2820461430>3.0.CO;2-4","volume":"46","author":"R Paridaens","year":"1980","unstructured":"Paridaens R, Sylvester R, Ferrazzi E, Legros N, Leclercq G, Henson J: Clinical significance of the quantitative assessment of estrogen receptors in advanced breast cancer.Cancer\n                           46 (Suppl), 2889 (1980).","journal-title":"Cancer"},{"key":"BF02934139_CR11","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1002\/1097-0142(19800615)45:12<2998::AID-CNCR2820451220>3.0.CO;2-I","volume":"45","author":"J McFarlane","year":"1980","unstructured":"McFarlane J, Fleiszer D, Fazekas A: Studies on estrogen receptors and regression in human breast cancer.Cancer\n                           45, 2998 (1980).","journal-title":"Cancer"},{"key":"BF02934139_CR12","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1002\/1097-0142(19801215)46:12+<2939::AID-CNCR2820461440>3.0.CO;2-5","volume":"46","author":"L Skinner","year":"1980","unstructured":"Skinner L, Barnes D, Ribeiro G: The clinical value of multiple steroid receptor assays in breast cancer management.Cancer\n                           46, 2939 (1980).","journal-title":"Cancer"},{"key":"BF02934139_CR13","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/bjc.1981.8","volume":"43","author":"R Leake","year":"1981","unstructured":"Leake R, Laing L, Calman K, Macbeth F, Crawford D, Smith D: Oestrogen-receptor status and endocrine therapy of breast cancer: response rates and status stability.Br J Cancer\n                           43, 59 (1981).","journal-title":"Br J Cancer"},{"key":"BF02934139_CR14","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1002\/1097-0142(19801215)46:12+<2789::AID-CNCR2820461409>3.0.CO;2-K","volume":"46","author":"G Degenshein","year":"1980","unstructured":"Degenshein G, Bloom N, Tobin E: The value of progesterone receptor assays in the management of advanced breast cancer.Cancer\n                           46 (Suppl), 2789 (1980).","journal-title":"Cancer"},{"key":"BF02934139_CR15","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.1002\/1097-0142(19800615)45:12<2992::AID-CNCR2820451218>3.0.CO;2-D","volume":"45","author":"N Bloom","year":"1980","unstructured":"Bloom N, Tobin E, Schreibman B, Degenshein G: The role of progesterone receptors in the management of advanced breast cancer.Cancer\n                           45, 2992 (1980).","journal-title":"Cancer"},{"key":"BF02934139_CR16","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/1097-0142(19810901)48:5<1215::AID-CNCR2820480527>3.0.CO;2-3","volume":"48","author":"A Sarrif","year":"1981","unstructured":"Sarrif A, Durant J: Evidence that estrogen-receptor-negative, progesterone-receptor-positive breast and ovarian carcinomas contain estrogen receptor.Cancer\n                           48, 1215 (1981).","journal-title":"Cancer"},{"key":"BF02934139_CR17","first-page":"108","volume":"2","author":"P Johnson","year":"1983","unstructured":"Johnson P, Bonomi P, Bacon L, Walter J, Anderson K, Economou S: Quantitative progesterone receptor level as a predictor of response to megestrol acetate or tamoxifen in advanced breast cancer.Proc ASCO\n                           2, 108 (1983).","journal-title":"Proc ASCO"},{"key":"BF02934139_CR18","first-page":"151","volume":"23","author":"R Paridaens","year":"1982","unstructured":"Paridaens R, Leclercq G, Legros N, Sylvester R, Henson J, Toma S: Estrogen receptor variation in neoplastic tissue during the course of disease in patients with recurrent breast cancer.Proc AACR\n                           23, 151 (1982).","journal-title":"Proc AACR"},{"key":"BF02934139_CR19","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1002\/1097-0142(19830801)52:3<479::AID-CNCR2820520317>3.0.CO;2-O","volume":"52","author":"I Holdaway","year":"1983","unstructured":"Holdaway I, Bowditch J: Variation in receptor status between primary and metastatic breast cancer.Cancer\n                           52, 479 (1983).","journal-title":"Cancer"},{"key":"BF02934139_CR20","first-page":"110","volume":"2","author":"G Gross","year":"1983","unstructured":"Gross G, Clark G, McGuire W: Multiple progesterone (PR) assays in human breast cancer.Proc ASCO\n                           2, 110 (1983).","journal-title":"Proc ASCO"},{"key":"BF02934139_CR21","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1002\/1097-0142(196409)17:9<1197::AID-CNCR2820170916>3.0.CO;2-T","volume":"17","author":"B Kennedy","year":"1964","unstructured":"Kennedy B, Fortuny I: Therapeutic castration in the treatment of advanced breast cancer.Cancer\n                           17, 1197 (1964).","journal-title":"Cancer"},{"key":"BF02934139_CR22","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/1097-0142(196901)23:1<145::AID-CNCR2820230119>3.0.CO;2-P","volume":"23","author":"H Harris","year":"1969","unstructured":"Harris H, Spratt J: Bilateral adrenalectomy in metastatic mammary cancer: an analysis of sixty-four cases.Cancer\n                           23, 145 (1969).","journal-title":"Cancer"},{"key":"BF02934139_CR23","first-page":"747","volume":"125","author":"A Fracchia","year":"1967","unstructured":"Fracchia A, Randall H, Farrow J: The results of adrenalectomy in advanced breast cancer in 500 consecutive patients.Surg Gynec Obs\n                           125, 747 (1967).","journal-title":"Surg Gynec Obs"},{"key":"BF02934139_CR24","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1002\/1097-0142(197912)44:6<2330::AID-CNCR2820440649>3.0.CO;2-G","volume":"44","author":"A Manni","year":"1979","unstructured":"Manni A, Pearson O, Brodkey J, Marshall J: Transphenoidal hypophysectomy in breast cancer: evidence for an individual role of pituitary and gonadal hormones in supporting tumor growth.Cancer\n                           44, 2330 (1979).","journal-title":"Cancer"},{"key":"BF02934139_CR25","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1001\/jama.1960.03020120049010","volume":"172","author":"Council on Drugs, Subcommittee on Breast and Genital Cancer, Committee on Research, AMA","year":"1960","unstructured":"Council on Drugs, Subcommittee on Breast and Genital Cancer, Committee on Research, AMA. Androgens and estrogens in the treatment of disseminated mammary carcinoma: retrospective study of nine hundred forty-four patients.J Am Med Assoc\n                           172, 1271 (1960).","journal-title":"J Am Med Assoc"},{"key":"BF02934139_CR26","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1002\/1097-0142(196512)18:12<1551::AID-CNCR2820181206>3.0.CO;2-1","volume":"18","author":"B Kennedy","year":"1965","unstructured":"Kennedy B: Hormone therapy for advanced breast cancer.Cancer\n                           18, 1551 (1965).","journal-title":"Cancer"},{"key":"BF02934139_CR27","first-page":"1","volume":"41","author":"Cooperative Breast Cancer Group","year":"1964","unstructured":"Cooperative Breast Cancer Group. Results of studies of the Cooperative Breast Cancer Group, 1961\u201363.Cancer Chemo Rep\n                           41 (Suppl) 1 (1964).","journal-title":"Cancer Chemo Rep"},{"key":"BF02934139_CR28","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1001\/jama.237.19.2079","volume":"237","author":"A Carter","year":"1977","unstructured":"Carter A, Sedransk N, Kelley R, Ansfeld F, Ravdin R, Talley R, Potter N: Diethylstilbestrol\u2014recommended dosages for different categories of breast cancer patients: Report of the Cooperative Breast Cancer Group.J Am Med Assoc\n                           237, 2079 (1977).","journal-title":"J Am Med Assoc"},{"key":"BF02934139_CR29","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1056\/NEJM198101013040104","volume":"304","author":"J Ingle","year":"1981","unstructured":"Ingle J, Ahmann D, Green S, Edmonson J, Bisel H, Krols L, Nichols W, Creagan E, Hahn R, Rubin J, Frytak S: Randomized clinical trial of diethylstilbestrol vs tamoxifen in postmenopausal women with advanced breast cancer.New Engl J Med\n                           304, 16 (1981).","journal-title":"New Engl J Med"},{"key":"BF02934139_CR30","first-page":"117","volume":"64","author":"H Westerberg","year":"1980","unstructured":"Westerberg H: Tamoxifen and fluoxymesterone in advanced breast cancer. A controlled clinical trial.Cancer Treat Rep\n                           64, 117 (1980).","journal-title":"Cancer Treat Rep"},{"key":"BF02934139_CR31","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/BF01805863","volume":"1","author":"D Tormey","year":"1981","unstructured":"Tormey D, Gelman R, Band P, Sears M, Bauer M, Arseneau J, Falkson G: A prospective evaluation of chemohormonal therapy remission maintenance in advanced breast cancer.Breast Cancer Res Treat\n                           1, 111 (1981).","journal-title":"Breast Cancer Res Treat"},{"key":"BF02934139_CR32","first-page":"779","volume":"64","author":"A Manni","year":"1980","unstructured":"Manni A, Pearson O: Antiestrogen-induced remission in premenopausal women with Stage IV breast cancer: effects on ovarian function.Cancer Treat Rep\n                           64, 779 (1980).","journal-title":"Cancer Treat Rep"},{"key":"BF02934139_CR33","first-page":"787","volume":"64","author":"K Pritchard","year":"1980","unstructured":"Pritchard K, Thomson D, Myers R, Sutherland D, Mobbs B, Meakin J: Tamoxifen therapy in premenopausal patients with metastatic breast cancer.Cancer Treat Rep\n                           64, 787 (1980).","journal-title":"Cancer Treat Rep"},{"key":"BF02934139_CR34","first-page":"4788","volume":"42","author":"B Hoogstraten","year":"1982","unstructured":"Hoogstraten B, Fletcher W, Gad-el-Mawla N, Maloney T, Altman S, Vaughn C, Foulkes M: Tamoxifen and oophorectomy in the treatment of recurrent breast cancer: a Southwest Oncology Group Study.Cancer Res\n                           42, 4788 (1982).","journal-title":"Cancer Res"},{"key":"BF02934139_CR35","first-page":"179","volume":"65","author":"L Beex","year":"1981","unstructured":"Beex L, Pieters G, Koenders A, Benraad T, Kloppenborg P: Tamoxifen versus ethinyl estradiol in the treatment of postmenopausal women with advanced breast cancer.Cancer Treat Rep\n                           65, 179 (1981).","journal-title":"Cancer Treat Rep"},{"key":"BF02934139_CR36","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0305-7372(76)80010-2","volume":"3","author":"S Legha","year":"1976","unstructured":"Legha S, Carter S: Antiestrogens in the treatment of breast cancer.Cancer Treat Rep\n                           3, 205 (1976).","journal-title":"Cancer Treat Rep"},{"key":"BF02934139_CR37","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/1097-0142(19810815)48:4<873::AID-CNCR2820480402>3.0.CO;2-1","volume":"48","author":"A Manni","year":"1981","unstructured":"Manni A, Arafah B: Tamoxifen-induced remission in breast cancer by escalating the dose to 40 mg daily after progression on 20 mg daily: a case report and review of the literature.Cancer\n                           48, 873 (1981).","journal-title":"Cancer"},{"key":"BF02934139_CR38","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1002\/1097-0142(19810815)48:4<876::AID-CNCR2820480403>3.0.CO;2-Q","volume":"48","author":"C Fabian","year":"1981","unstructured":"Fabian C, Sternson L, El-Serafi M, Cain L, Hearne E: Clinical pharmacology of tamoxifen in patients with breast cancer: correlation with clinical data.Cancer\n                           48, 876 (1981).","journal-title":"Cancer"},{"key":"BF02934139_CR39","doi-asserted-by":"crossref","first-page":"94","DOI":"10.7326\/0003-4819-96-1-94","volume":"96","author":"R Santen","year":"1982","unstructured":"Santen R, Worgul T, Lipton A, Harvey H, Boucher A, Samojlik E, Wells S: Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma.Ann Int Med\n                           96, 94 (1982).","journal-title":"Ann Int Med"},{"key":"BF02934139_CR40","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1002\/1097-0142(19810415)47:8<1954::AID-CNCR2820470807>3.0.CO;2-E","volume":"47","author":"R Asbury","year":"1981","unstructured":"Asbury R, Bakemeier R, Folsch E, McCune C, Savlov E, Bennett J: Treatment of metastatic breast cancer with aminoglutethimide.Cancer\n                           47, 1954 (1981).","journal-title":"Cancer"},{"key":"BF02934139_CR41","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJM198109033051003","volume":"305","author":"R Santen","year":"1981","unstructured":"Santen R, Worgul T, Samojlik E, Interrante A, Boucher A, Lipton A, Harvey H, White D, Smart E, Cox C, Wells S: A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer.New Engl J Med\n                           305, 545 (1981).","journal-title":"New Engl J Med"},{"key":"BF02934139_CR42","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1002\/1097-0142(19821201)50:11<2265::AID-CNCR2820501106>3.0.CO;2-#","volume":"50","author":"A Lipton","year":"1982","unstructured":"Lipton A, Harvey H, Santen R, Boucher A, White D, Bernath A, Dixon R, Richards G, Shafik A: A randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer.Cancer\n                           50, 2265 (1982).","journal-title":"Cancer"},{"key":"BF02934139_CR43","first-page":"3442","volume":"42","author":"G Nagel","year":"1982","unstructured":"Nagel G, Wander H, Blossey H C: Phase II study of aminoglutethimide and medroxyprogesterone acetate in the treatment of patients with advanced breast cancer.Cancer Res\n                           42, (Suppl), 3442 (1982).","journal-title":"Cancer Res"},{"key":"BF02934139_CR44","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1002\/1097-0142(19801201)46:11<2369::AID-CNCR2820461111>3.0.CO;2-3","volume":"46","author":"J Alexiera-Figusch","year":"1980","unstructured":"Alexiera-Figusch J, van Gilse H, Hop W, Phoa C, Wijst S, Treurniet R: Progestin therapy in advanced breast cancer: megestrol acetate\u2014an evaluation of 160 treated cases.Cancer\n                           46, 2369 (1980).","journal-title":"Cancer"},{"key":"BF02934139_CR45","first-page":"499","volume":"62","author":"F Pannuti","year":"1978","unstructured":"Pannuti F, Martoni A, Lenaz G, Piana E, Nanni P: A possible new approach to the treatment of metastatic breast cancer: massive doses of medroxyprogesterone acetate.Cancer Treat Rep\n                           62, 499 (1978).","journal-title":"Cancer Treat Rep"},{"key":"BF02934139_CR46","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/BF01805865","volume":"1","author":"M Izuo","year":"1981","unstructured":"Izuo M, Iino Y, Endo K: Oral high dose medroxyprogesterone acetate (MAP) in treatment of advanced breast cancer.Breast Cancer Res Treat\n                           1, 125 (1981).","journal-title":"Breast Cancer Res Treat"},{"key":"BF02934139_CR47","unstructured":"Wander H, Blossey C, Koberling J, Nagel G: High dose medroxyprogesterone acetate in metastatic breast cancer: correlations between tumor response and endocrine parameters.Klin Wochensch (in press)."},{"key":"BF02934139_CR48","first-page":"135","volume":"65","author":"A Pellegrini","year":"1981","unstructured":"Pellegrini A, Massidda B, Mascia V, Ionta M, Lippi M, Muggiano A, Carboni E, della Cuna G, Bernardo G, Strada M, Pavesi L: Ethinyl estradiol and medroxyprogesterone treatments in advanced breast cancer: a pilot study.Cancer Treat Rep\n                           65, 135 (1981).","journal-title":"Cancer Treat Rep"},{"key":"BF02934139_CR49","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/S0140-6736(82)92339-X","volume":"i","author":"J Klijn","year":"1982","unstructured":"Klijn J, De Jong F: Treatment with a luteinizing hormone-releasing hormone analogue (Buserelin) in premenopausal patients with metastatic breast cancer.Lancet\n                           i 1213 (1982).","journal-title":"Lancet"},{"key":"BF02934139_CR50","first-page":"444","volume":"22","author":"H Harvey","year":"1981","unstructured":"Harvey H, Lipton A, Santen R, Escher G, Hardy M, Glade L, Segaloff A, Landan R, Schreier H, Max D: Phase II study of a gonadotropin-releasing hormone analogue (Leuprolide) in postmenopausal advanced breast cancer patients.Proc ASCO\n                           22, 444 (1981).","journal-title":"Proc ASCO"},{"key":"BF02934139_CR51","first-page":"447","volume":"22","author":"W Paladine","year":"1981","unstructured":"Paladine W, Ayres V, Price L, Drapkin R, Sokol G, Kriz E, Scheinbaum M: Danazol, an inhibitor of LH and FSH in the treatment of recurrent or metastatic breast carcinoma.Proc ASCO\n                           22, 447 (1981).","journal-title":"Proc ASCO"},{"key":"BF02934139_CR52","first-page":"139","volume":"22","author":"G Nagel","year":"1982","unstructured":"Nagel G, Holtkamp W, Wander H, Blossey C: Hyperprolactinemia and bromocryptine in metastatic breast cancer.Proc AACR\n                           22, 139 (1982).","journal-title":"Proc AACR"},{"key":"BF02934139_CR53","first-page":"554","volume":"71","author":"T Nemoto","year":"1971","unstructured":"Nemoto T, Dao T: 5-fluorouracil and cyclophosphamide in disseminated breast cancer.N Y State J Med\n                           71, 554 (1971).","journal-title":"N Y State J Med"},{"key":"BF02934139_CR54","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1002\/1097-0142(197805)41:5<1649::AID-CNCR2820410501>3.0.CO;2-J","volume":"41","author":"J Bull","year":"1978","unstructured":"Bull J, Tormey D, Li S, Carbone P, Falkson G, Blom J, Perlin E, Simon R: A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy.Cancer\n                           41, 1649 (1978).","journal-title":"Cancer"},{"key":"BF02934139_CR55","first-page":"1552","volume":"39","author":"K Swenerton","year":"1979","unstructured":"Swenerton K, Legha S, Smith T, Hortobagyi G, Gehan E, Yap H, Gutterman J, Blumenschein G: Prognostic factors in metastatic breast cancer treated with combination chemotherapy.Cancer Res\n                           39, 1552 (1979).","journal-title":"Cancer Res"},{"key":"BF02934139_CR56","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1002\/1097-0142(19801201)46:11<2380::AID-CNCR2820461113>3.0.CO;2-M","volume":"46","author":"C Nash","year":"1980","unstructured":"Nash C, Jones S, Moon T, Davis S, Salmon S: Prediction of outcome in metastatic breast cancer treated with adriamycin combination chemotherapy.Cancer\n                           46, 2380 (1980).","journal-title":"Cancer"},{"key":"BF02934139_CR57","doi-asserted-by":"crossref","first-page":"784","DOI":"10.7326\/0003-4819-86-6-784","volume":"86","author":"D Tormey","year":"1977","unstructured":"Tormey D: Single agent chemotherapy and comparison with combination therapy in advanced breast cancer.Ann Int Med\n                           86, 784 (1977).","journal-title":"Ann Int Med"},{"key":"BF02934139_CR58","first-page":"111","volume":"64","author":"A Manni","year":"1980","unstructured":"Manni A, Trujillo J, Pearson O: Sequential use of endocrine therapy and chemotherapy for metastatic breast cancer: effects on survival.Cancer Treat Rep\n                           64, 111 (1980).","journal-title":"Cancer Treat Rep"},{"key":"BF02934139_CR59","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1002\/1097-0142(19800801)46:3<438::AID-CNCR2820460303>3.0.CO;2-P","volume":"46","author":"S Legha","year":"1980","unstructured":"Legha S, Buzdar A, Smith T, Swenerton K, Hortobagyi G, Blumenschein G: Response to hormonal therapy as a prognostic factor for metastatic breast cancer treated with combination chemotherapy.Cancer\n                           46, 438 (1980).","journal-title":"Cancer"},{"key":"BF02934139_CR60","first-page":"143","volume":"23","author":"R Steiner","year":"1982","unstructured":"Steiner R, Stewart J, Rubens R: Does response to endocrine therapy predict response to chemotherapy in advanced breast cancer?Proc AACR\n                           23, 143 (1982).","journal-title":"Proc AACR"},{"key":"BF02934139_CR61","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1056\/NEJM197806012982203","volume":"298","author":"M Lippman","year":"1978","unstructured":"Lippman M, Allegra J, Thompson E, Simon R, Barlock A, Green L, Huff K, Do H, Aitken S, Warren R: The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer.New Engl J Med\n                           298, 1223 (1978).","journal-title":"New Engl J Med"},{"key":"BF02934139_CR62","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1002\/1097-0142(19801215)46:12+<2814::AID-CNCR2820461415>3.0.CO;2-D","volume":"46","author":"D Kiang","year":"1980","unstructured":"Kiang D, Frenning D, Gay J, Goldman A, Kennedy B: Estrogen receptor status and response to chemotherapy in advanced breast cancer.Cancer\n                           46 (Suppl), 2814 (1980).","journal-title":"Cancer"},{"key":"BF02934139_CR63","first-page":"763","volume":"65","author":"J Mortimer","year":"1981","unstructured":"Mortimer J, Reimer R, Greenstreet R, Groppe C, Bukowski R: Influence of estrogen receptor status on response to combination chemotherapy for recurrent breast cancer.Cancer Treat Rep\n                           65, 763 (1981).","journal-title":"Cancer Treat Rep"},{"key":"BF02934139_CR64","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1002\/1097-0142(19811201)48:11<2503::AID-CNCR2820481126>3.0.CO;2-T","volume":"48","author":"J Chang","year":"1981","unstructured":"Chang J, Wergowske G: Correlation of estrogen receptors and response to chemotherapy of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in advanced breast cancer.Cancer\n                           48, 2503 (1981).","journal-title":"Cancer"},{"key":"BF02934139_CR65","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1002\/1097-0142(19801215)46:12+<2809::AID-CNCR2820461414>3.0.CO;2-2","volume":"46","author":"W Jonat","year":"1980","unstructured":"Jonat W, Maass H, Stolzenbach G, Trams G: Estrogen receptor status and response to polychemotherapy in advanced breast cancer.Cancer\n                           46 (Suppl), 2809 (1980).","journal-title":"Cancer"},{"key":"BF02934139_CR66","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1002\/1097-0142(19801215)46:12+<2797::AID-CNCR2820461411>3.0.CO;2-B","volume":"46","author":"R Hilf","year":"1980","unstructured":"Hilf R, Feldstein M, Savlov E, Gibson S, Seneca B: The lack of relationship between estrogen receptor status and response to chemotherapy.Cancer\n                           46 (Suppl), 2797 (1980).","journal-title":"Cancer"},{"key":"BF02934139_CR67","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1200\/JCO.1983.1.2.75","volume":"1","author":"J F Holland","year":"1983","unstructured":"Holland J F: Breaking the cure barrier.J Clin Onc\n                           1, 75 (1983).","journal-title":"J Clin Onc"},{"key":"BF02934139_CR68","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1002\/1097-0142(197212)30:6<1543::AID-CNCR2820300621>3.0.CO;2-V","volume":"30","author":"S Carter","year":"1972","unstructured":"Carter S: Single and combination nonhormonal chemotherapy in breast cancer.Cancer\n                           30, 1543 (1972).","journal-title":"Cancer"},{"key":"BF02934139_CR69","first-page":"3","volume":"15","author":"P Coggins","year":"1961","unstructured":"Coggins P, Eisman S, Elkins W, Ravdin R: Cyclophosphamide therapy in carcinoma of the breast and ovary\u2014a comparative study of intermittent massive vs continuous maintenance dosage regimens.Cancer Chemo Rep\n                           15, 3 (1961).","journal-title":"Cancer Chemo Rep"},{"key":"BF02934139_CR70","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/bjc.1970.57","volume":"24","author":"B Stoll","year":"1970","unstructured":"Stoll B: Evaluation of cyclophosphamide dosage schedules in breast cancer.Br J Cancer\n                           24, 478 (1970).","journal-title":"Br J Cancer"},{"key":"BF02934139_CR71","first-page":"1","volume":"35","author":"H Skipper","year":"1964","unstructured":"Skipper H, Schabel F, Wilcox W: Experimental evaluation of potential anticancer agents. XIII. On the criteria and kinetics associated with \u201ccurability\u201d of experimental leukemia.Cancer Chemo Rep\n                           35, 1 (1964).","journal-title":"Cancer Chemo Rep"},{"key":"BF02934139_CR72","first-page":"661","volume":"52","author":"G Moore","year":"1968","unstructured":"Moore G, Bross D, Ausman R, Nadler S, Jones R, Slack N, Rimm H: Effects of chlorambucil (NSC-3088) in 374 patients with advanced cancer: Eastern Clinical Drug Evaluation Program.Cancer Chemo Rep (Part 1) 52, 661 (1968).","journal-title":"Cancer Chemo Rep"},{"key":"BF02934139_CR73","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/0021-9681(60)90137-5","volume":"11","author":"C Zubrod","year":"1966","unstructured":"Zubrod C: Appraisal of methods for the study of chemotherapy in man: comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide.J Chron Dis\n                           11, 7 (1966).","journal-title":"J Chron Dis"},{"key":"BF02934139_CR74","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1001\/archsurg.1961.01300160123015","volume":"83","author":"J Hurley","year":"1961","unstructured":"Hurley J: A method of selecting patients for cancer chemotherapy.Arch Surg\n                           83, 611 (1961).","journal-title":"Arch Surg"},{"key":"BF02934139_CR75","first-page":"271","volume":"50","author":"M Sears","year":"1966","unstructured":"Sears M, Haut A, Eckles N: Melphalan (NSC-8806) in advanced breast cancer.Cancer Chemo Rep\n                           50, 271 (1966).","journal-title":"Cancer Chemo Rep"},{"key":"BF02934139_CR76","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1002\/1097-0142(197611)38:5<1882::AID-CNCR2820380503>3.0.CO;2-H","volume":"38","author":"G Canellos","year":"1976","unstructured":"Canellos G, Pocock S, Taylor S, Sears M, Klaasen D, Band P: Combination chemotherapy for metastatic breast carcinoma: prospective comparison of multiple drug therapy withl-phenylalanine mustard.Cancer\n                           38, 1882 (1976).","journal-title":"Cancer"},{"key":"BF02934139_CR77","first-page":"478","volume":"18","author":"A Curreri","year":"1958","unstructured":"Curreri A, Ansfield F, McIver F, Waisman H, Heidelberger C: Clinical studies with 5-fluorouracil.Cancer Res\n                           18, 478 (1958).","journal-title":"Cancer Res"},{"key":"BF02934139_CR78","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1001\/jama.1964.03070200122030","volume":"190","author":"F Ansfield","year":"1964","unstructured":"Ansfield F: A less toxic fluorouracil dosage schedule.J Am Med Assoc\n                           190, 686 (1964).","journal-title":"J Am Med Assoc"},{"key":"BF02934139_CR79","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1002\/1097-0142(197106)27:6<1302::AID-CNCR2820270604>3.0.CO;2-5","volume":"27","author":"E Jacobs","year":"1971","unstructured":"Jacobs E, Reeves W, Wood D: Treatment of cancer with weekly intravenous 5-fluorouracil.Cancer\n                           27, 1302 (1971).","journal-title":"Cancer"},{"key":"BF02934139_CR80","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/1097-0142(197701)39:1<34::AID-CNCR2820390107>3.0.CO;2-2","volume":"39","author":"F Ansfield","year":"1977","unstructured":"Ansfield F, Klotz J, Nealon T, Ramirez G, Minton J, Hill G, Wilson W, Davis H, Cornell G: A Phase III study comparing the clinical utility of four regimens of 5-fluorouracil: a preliminary report.Cancer\n                           39, 34 (1977).","journal-title":"Cancer"},{"key":"BF02934139_CR81","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1002\/1097-0142(19811015)48:8<1711::AID-CNCR2820480804>3.0.CO;2-C","volume":"48","author":"R Chlebowski","year":"1981","unstructured":"Chlebowski R, Pugh R, Weiner J, Bateman J: Treatment of advanced breast cancer with 5-fluorouracil: a randomized comparison of two routes of delivery.Cancer\n                           48, 1711 (1981).","journal-title":"Cancer"},{"key":"BF02934139_CR82","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/cpt196566740","volume":"6","author":"R Talley","year":"1965","unstructured":"Talley R, Vaitkevicius V, Leighton G: Comparison of cyclophosphamide and 5-fluorouracil in the treatment of patients with metastatic breast cancer.Clin Pharm Ther\n                           6, 740 (1965).","journal-title":"Clin Pharm Ther"},{"key":"BF02934139_CR83","first-page":"757","volume":"63","author":"H Yap","year":"1979","unstructured":"Yap H, Blumenschein G, Yap B, Hortobagyi G, Tashima C, Waring A, Benjamin R, Bodey G: High-dose methotrexate for advanced breast cancer.Cancer Treat Rep\n                           63, 757 (1979).","journal-title":"Cancer Treat Rep"},{"key":"BF02934139_CR84","first-page":"37","volume":"6","author":"R Capizzi","year":"1975","unstructured":"Capizzi R: Improvement in the therapeutic index of methotrexate (NSC-740) byl-asparaginase (NSC-109229).Cancer Chemo Rep (Part 3),6, 37 (1975).","journal-title":"Cancer Chemo Rep"},{"key":"BF02934139_CR85","first-page":"77","volume":"63","author":"H Yap","year":"1979","unstructured":"Yap H, Benjamin R, Blumenschein G, Hortobagyi G, Tashima C, Buzdar A, Bodey G: Phase II study with sequentiall-asparaginase and methotrexate in advanced refractory breast cancer.Cancer Treat Rep\n                           63, 77 (1979).","journal-title":"Cancer Treat Rep"},{"key":"BF02934139_CR86","first-page":"1258","volume":"33","author":"J F Holland","year":"1973","unstructured":"Holland J F, Scharlan C, Gailani S, Krant M, Olson K, Horton J, Schnider B, Lynch J, Owens A, Carbone P, Colsky J, Grob D, Miller S, Hall T: Vincristine treatment of advanced cancer: a cooperative study of 392 cases.Cancer Res\n                           33, 1258 (1973).","journal-title":"Cancer Res"},{"key":"BF02934139_CR87","first-page":"57","volume":"45","author":"R Grinberg","year":"1965","unstructured":"Grinberg R, Nemoto T, Dao T: Vincristine (NSC-67574): dosage and response in advanced breast cancer.Cancer Chemo Rep\n                           45, 57 (1965).","journal-title":"Cancer Chemo Rep"},{"key":"BF02934139_CR88","first-page":"279","volume":"64","author":"H Yap","year":"1980","unstructured":"Yap H, Blumenschein G, Keating M, Hortobagyi G, Tashima C, Loo T: Vinblastine given as a continuous 5-day infusion in the treatment of refractory advanced breast cancer.Cancer Treat Rep\n                           64, 279 (1980).","journal-title":"Cancer Treat Rep"},{"key":"BF02934139_CR89","first-page":"78","volume":"1","author":"G Fraschini","year":"1982","unstructured":"Fraschini G, Yap H, Barnes B, Buzdar A, Hortobagyi H, Blumenschein G: Continuous 5-day infusion of vinblastine for refractory metastatic breast cancer.Proc ASCO\n                           1, 78 (1982).","journal-title":"Proc ASCO"},{"key":"BF02934139_CR90","first-page":"1783","volume":"66","author":"I Tannock","year":"1982","unstructured":"Tannock I, Erlichman C, Perrault D, Quirt I, King M: Failure of 5-day vinblastine infusion in the treatment of patients with advanced refractory breast cancer.Cancer Treat Rep\n                           66, 1783 (1982).","journal-title":"Cancer Treat Rep"},{"key":"BF02934139_CR91","first-page":"83","volume":"1","author":"D White","year":"1982","unstructured":"White D, Hopkins J, Jackson D, Muss H, Richards F, Cooper M, Stuart J, Spurr C: Vincristine by continuous infusion in refractory breast cancer: a phase II study.Proc ASCO\n                           1, 83 (1982).","journal-title":"Proc ASCO"},{"key":"BF02934139_CR92","first-page":"1729","volume":"66","author":"B Walker","year":"1982","unstructured":"Walker B, Raich P, Fontana J, Subramanian V, Rogers J, Knost J, Denning B: Phase II study of vindesine in patients with advanced breast cancer.Cancer Treat Rep\n                           66, 1729 (1982).","journal-title":"Cancer Treat Rep"},{"key":"BF02934139_CR93","first-page":"1427","volume":"62","author":"I Smith","year":"1978","unstructured":"Smith I, Hedley D, Powles T, McElwain T: Vindesine: a Phase II study in the treatment of breast carcinoma, malignant melanoma, and other tumors.Cancer Treat Rep\n                           62, 1427 (1978).","journal-title":"Cancer Treat Rep"},{"key":"BF02934139_CR94","first-page":"659","volume":"65","author":"M Cobleigh","year":"1981","unstructured":"Cobleigh M, Williams S, Einhorn L: Phase II study of vindesine in patients with metastatic breast cancer.Cancer Treat Rep\n                           65, 659 (1981).","journal-title":"Cancer Treat Rep"},{"key":"BF02934139_CR95","first-page":"775","volume":"65","author":"H Yap","year":"1981","unstructured":"Yap H, Blumenschein G, Bodey G, Hortobagyi G, Buzdar A, DiStefano A: Vindesine in the treatment of refractory breast cancer: improvement in therapeutic index with continuous 5-day infusion.Cancer Treat Rep\n                           65, 775 (1981).","journal-title":"Cancer Treat Rep"},{"key":"BF02934139_CR96","first-page":"319","volume":"6","author":"D Tormey","year":"1975","unstructured":"Tormey D: A driamycin (NSC-123127) in breast cancer: an overview of studies.Cancer Chemo Rep (Part 3),6, 319 (1975).","journal-title":"Cancer Chemo Rep"},{"key":"BF02934139_CR97","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/1097-0142(197607)38:1<13::AID-CNCR2820380104>3.0.CO;2-5","volume":"38","author":"B Hoogstraten","year":"1976","unstructured":"Hoogstraten B, George S, Samal B, Rivkin S, Costanzi J, Bonnet J, Thigpen T, Braine H: Combination chemotherapy and adriamycin in patients with advanced breast cancer: a Southwest Oncology Group Study.Cancer\n                           38, 13 (1976).","journal-title":"Cancer"},{"key":"BF02934139_CR98","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/1097-0142(197402)33:2<519::AID-CNCR2820330229>3.0.CO;2-X","volume":"33","author":"J Gottlieb","year":"1974","unstructured":"Gottlieb J, Rivkin S, Spigel S, Hoogstraten B, O'Bryan R, Delaney F, Singhakowinta A: Superiority of adriamycin over oral nitrosoureas in patients with advanced breast cancer: a Southwest Cancer Chemotherapy Group Study.Cancer\n                           33, 519 (1974).","journal-title":"Cancer"},{"key":"BF02934139_CR99","first-page":"121","volume":"63","author":"E Knight","year":"1979","unstructured":"Knight E, Horton J, Cunningham T, Rhie F, Lagakos S, Rosenbaum C, Taylor S, Tennant J: Adriamycin: comparison of a 5-week schedule with a 3-week schedule in the treatment of breast cancer.Cancer Treat Rep\n                           63, 121 (1979).","journal-title":"Cancer Treat Rep"},{"key":"BF02934139_CR100","first-page":"1701","volume":"63","author":"J Ingle","year":"1979","unstructured":"Ingle J, Ahmann D, O'Fallon J, Bisel H, Rubin J, Krols L, Guiliano E: Randomized Phase II trial of rubidazone and adriamycin in women with advanced breast cancer.Cancer Treat Rep\n                           63, 1701 (1979).","journal-title":"Cancer Treat Rep"},{"key":"BF02934139_CR101","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1002\/1097-0142(197806)41:6<2073::AID-CNCR2820410601>3.0.CO;2-7","volume":"41","author":"T Nemoto","year":"1978","unstructured":"Nemoto T, Rosner D, Diaz R, Dao T, Sponzo R, Cunningham T, Horton J, Simon R: Combination chemotherapy for metastatic breast cancer: comparison of multiple drug therapy with 5-fluorouracil, cytotoxan and prednisone with adriamycin or adrenalectomy.Cancer\n                           41, 2073 (1978).","journal-title":"Cancer"},{"key":"BF02934139_CR102","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/1097-0142(19800801)46:3<433::AID-CNCR2820460302>3.0.CO;2-6","volume":"46","author":"R Creech","year":"1980","unstructured":"Creech R, Catalano R, Shah M: An effective low-dose adriamycin regimen as secondary chemotherapy for metastatic breast cancer patients.Cancer\n                           46, 433 (1980).","journal-title":"Cancer"},{"key":"BF02934139_CR103","first-page":"142","volume":"21","author":"R Creech","year":"1980","unstructured":"Creech R, Catalano R, Hopson R: A comparison of standard dose adriamycin (SDA) and low dose adriamycin (LDA) as primary chemotherapy for metastatic breast cancer.Proc AACR\n                           21, 142 (1980).","journal-title":"Proc AACR"},{"key":"BF02934139_CR104","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1002\/1097-0142(19820501)49:9<1762::AID-CNCR2820490905>3.0.CO;2-Q","volume":"49","author":"S Legha","year":"1982","unstructured":"Legha S, Benjamin R, Mackay B, Yap H, Wallace S, Ewer M, Blumenschein G, Freireich E: Adriamycin therapy by continuous intravenous infusion in patients with metastatic breast cancer.Cancer\n                           49, 1762 (1982).","journal-title":"Cancer"},{"key":"BF02934139_CR105","first-page":"877","volume":"58","author":"D Ahmann","year":"1979","unstructured":"Ahmann D, Bisel H, Eagan R, Edmonson T, Hahn R: Controlled evaluation of adriamycin (NSC-123127) in patients with disseminated breast cancer.Cancer Chemo Rep\n                           58, 877 (1979).","journal-title":"Cancer Chemo Rep"},{"key":"BF02934139_CR106","first-page":"107","volume":"2","author":"R Jones","year":"1983","unstructured":"Jones R, Norton L, Bhardwaj S, Mass T, Holland J: Single agent adriamycin for metastatic breast cancer. A steep dose-response relationship.Proc ASCO\n                           2, 107 (1983).","journal-title":"Proc ASCO"},{"key":"BF02934139_CR107","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/BF00255480","volume":"8","author":"R Stuart-Harris","year":"1982","unstructured":"Stuart-Harris R, Smith I: Mitoxantrone: a Phase II study in the treatment of patients with advanced breast carcinoma and other solid tumors.Cancer Chemo Pharm\n                           8, 179 (1982).","journal-title":"Cancer Chemo Pharm"},{"key":"BF02934139_CR108","first-page":"87","volume":"1","author":"W Knight","year":"1982","unstructured":"Knight W, Von Hoff D, Tranum B, O'Bryan R: A Phase II trial of dihydroxyanthracenedione (DHAD, mitoxantrone) in breast cancer: a Southwest Oncology Group (SWOG) Study,Proc ASCO\n                           1, 87 (1982).","journal-title":"Proc ASCO"},{"key":"BF02934139_CR109","first-page":"100","volume":"2","author":"R Stuart-Harris","year":"1983","unstructured":"Stuart-Harris R, Smith I, Cornbleet M, Smyth J, Rubens R: Mitoxantrone, an active well tolerated new drug in advancing breast cancer: a Phase II study in patients receiving no previous chemotherapy.Proc ASCO\n                           2, 100 (1983).","journal-title":"Proc ASCO"},{"key":"BF02934139_CR110","first-page":"87","volume":"1","author":"C Osborne","year":"1982","unstructured":"Osborne C, Von Hoff D, Sandback J: Activity of bisantrene in a Phase II study in advanced breast cancer.Proc. ASCO\n                           1, 87 (1982).","journal-title":"Proc. ASCO"},{"key":"BF02934139_CR111","first-page":"1402","volume":"43","author":"H Yap","year":"1983","unstructured":"Yap H, Yap B, Blumenschein G, Barnes B, Schell F, Bodey G: Bisantrene, an active new drug in the treatment of metastatic breast cancer.Cancer Res\n                           43, 1402 (1983).","journal-title":"Cancer Res"},{"key":"BF02934139_CR112","first-page":"675","volume":"52","author":"G Moore","year":"1968","unstructured":"Moore G, Bross D, Ausman R, Nadler S, Jones R, Slack N, Rimm A: Effects of mitomycin C (NSC-26980) in 346 patients with advanced cancer. Eastern Clinical Oncology Evaluation Program.Cancer Chemo Rep (Part I)52, 675 (1968).","journal-title":"Cancer Chemo Rep (Part I)"},{"key":"BF02934139_CR113","first-page":"88","volume":"1","author":"R Creech","year":"1982","unstructured":"Creech R, Catalano R, Shah M, Dayal H: A randomized trial of adriamycin vs mitomycin at low doses in CMF refractory metastatic breast cancer patients.Proc ASCO\n                           1, 88 (1982).","journal-title":"Proc ASCO"},{"key":"BF02934139_CR114","first-page":"249","volume":"4","author":"V Currie","year":"1981","unstructured":"Currie V, Howard J, Wittes R: A Phase II evaluation ofm-AMSA, 4\u2032-(9-acridinylamino)methanesulfon-m-anisidide, in patients with breast cancer.Cancer Clin Trials\n                           4, 249 (1981).","journal-title":"Cancer Clin Trials"},{"key":"BF02934139_CR115","first-page":"1961","volume":"63","author":"S Legha","year":"1979","unstructured":"Legha S, Blumenschein G, Buzdar A, Hortobagyi G, Bodey G: Phase II study of 4\u2032-(9-acridinylamino) methane-sulfon-m-anisidide (AMSA) in metastatic breast cancer.Cancer Treat Rep\n                           63, 1961 (1979).","journal-title":"Cancer Treat Rep"},{"key":"BF02934139_CR116","first-page":"633","volume":"60","author":"D Ahmann","year":"1976","unstructured":"Ahmann D, Bisel H, Bacon R, Edmonson J, Hahn R, O'Connell M, Frytak S: Phase II evaluation of VP-16-213 (NSC-141540) and cytembena (NSC-104801) in patients with advanced breast cancer.Cancer Treat Rep\n                           60, 633 (1976).","journal-title":"Cancer Treat Rep"},{"key":"BF02934139_CR117","first-page":"443","volume":"65","author":"L Vaughn","year":"1981","unstructured":"Vaughn L, Panettiere F, Thigpen T, Bottomley R, Hoogstraten B, Samal B: Phase II evaluation of VP-16-213 in patients with advanced breast cancer: a Southwest Oncology Group Study.Cancer Treat Rep\n                           65, 443 (1981).","journal-title":"Cancer Treat Rep"},{"key":"BF02934139_CR118","first-page":"465","volume":"65","author":"H Yap","year":"1981","unstructured":"Yap H, Blumenschein G, Schnell F, Bodey G: Phase II evaluation of methyl-GAG in patients with refractory metastatic breast cancer.Cancer Treat Rep\n                           65, 465 (1981).","journal-title":"Cancer Treat Rep"},{"key":"BF02934139_CR119","first-page":"405","volume":"62","author":"H Yap","year":"1978","unstructured":"Yap H, Salem P, Hortobagyi G, Bodey G, Buzdar A, Tashima C, Blumenschein G: Phase II study ofcis-dichlorodiammineplatinum (II) in advanced breast cancer.Cancer Treat Rep\n                           62, 405 (1978).","journal-title":"Cancer Treat Rep"},{"key":"BF02934139_CR120","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1097\/00000658-197106010-00008","volume":"173","author":"W Shingleton","year":"1971","unstructured":"Shingleton W, Sedranks N, Johnson R: Systemic chemotherapy of mammary carcinoma.Ann Surg\n                           173, 913 (1971).","journal-title":"Ann Surg"},{"key":"BF02934139_CR121","first-page":"173","volume":"62","author":"J Denefrio","year":"1978","unstructured":"Denefrio J, Vogel C: Phase II study of hexamethylmelamine in women with advanced breast cancer refractory to standard cytotoxic therapy.Cancer Treat Rep\n                           62, 173 (1978).","journal-title":"Cancer Treat Rep"},{"key":"BF02934139_CR122","first-page":"2053","volume":"63","author":"S Legha","year":"1979","unstructured":"Legha S, Buzdar A, Hortobagyi G, Di Stefano A, Wiseman C, Yap H, Blumenschein G, Bodey G: Phase II study of hexamethylmelamine alone and in combination with mitomycin C and vincristine in advanced breast carcinoma.Cancer Treat Rep\n                           63, 2053 (1979).","journal-title":"Cancer Treat Rep"},{"key":"BF02934139_CR123","first-page":"1359","volume":"63","author":"C Fabian","year":"1977","unstructured":"Fabian C, Rasmussen S, Stephens R, Haut A, Smith F, Balcerzak S, Tranum B: Phase II evaluation of hexamethylmelamine in advanced breast cancer: a Southwest Oncology Group Study.Cancer Treat Rep\n                           63, 1359 (1977).","journal-title":"Cancer Treat Rep"},{"key":"BF02934139_CR124","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/00000421-198206000-00001","volume":"5","author":"A Forestiere","year":"1982","unstructured":"Forestiere A, Hakes T, Wittes J, Wittes R: Cisplatin in the treatment of metastatic breast carcinoma. A prospective randomized trial of two dosage schedules.Am J Clin Oncol\n                           5, 243 (1982).","journal-title":"Am J Clin Oncol"},{"key":"BF02934139_CR125","first-page":"730","volume-title":"Cancer Medicine","author":"R Blum","year":"1982","unstructured":"Blum R, Frei E, Holland J F: Principles of dose schedule and combination chemotherapy, in Holland J and Frei E (eds)Cancer Medicine, pp. 730\u2013752, Philadelphia, Lea & Feibiger (1982)."},{"key":"BF02934139_CR126","first-page":"1","volume":"33","author":"E Greenspan","year":"1966","unstructured":"Greenspan E: Combination cytotoxic chemotherapy in advanced disseminated breast carcinoma.J Mt Sinai Hosp\n                           33, 1 (1966).","journal-title":"J Mt Sinai Hosp"},{"key":"BF02934139_CR127","unstructured":"Leone L, Falkson G, Glidewell O, Holland J F: CALGB unpublished data."},{"key":"BF02934139_CR128","first-page":"15","volume":"10","author":"R Cooper","year":"1969","unstructured":"Cooper R: Combination chemotherapy in hormone resistant breast cancer.Proc AACR\n                           10, 15 (1969).","journal-title":"Proc AACR"},{"key":"BF02934139_CR129","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/1097-0142(197408)34:2<239::AID-CNCR2820340202>3.0.CO;2-E","volume":"34","author":"H Davis","year":"1974","unstructured":"Davis H, Ramirez G, Ellerby R, Ansfield F: Five-drug therapy in advanced breast cancer. Factors, influences, toxicity and response.Cancer\n                           34, 239 (1974).","journal-title":"Cancer"},{"key":"BF02934139_CR130","first-page":"3911","volume":"36","author":"R Smalley","year":"1976","unstructured":"Smalley R, Murphy S, Huguley C, Bartolucci A: Combination versus sequential five-drug chemotherapy in metastatic carcinoma of the breast.Cancer Res\n                           36, 3911 (1976).","journal-title":"Cancer Res"},{"key":"BF02934139_CR131","first-page":"73","volume":"1","author":"M Perloff","year":"1982","unstructured":"Perloff M, Norton L, Bushkin E, Holland J: Intensive six-week courses of combination chemotherapy in Stage IV breast carcinoma.Proc ASCO\n                           1, 73 (1982).","journal-title":"Proc ASCO"},{"key":"BF02934139_CR132","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1002\/cncr.2820360901","volume":"36","author":"D Ahmann","year":"1975","unstructured":"Ahmann D, Bisel H, Hahn R, Eagan T, Edmonson J, Steinfeld J, Tormey D, Taylor W: An analysis of a multiple drug program in the treatment of patients with advanced breast cancer utilizing 5-fluorouracil, cyclophosphamide and prednisone with or without vincristine.Cancer\n                           36, 1925 (1975).","journal-title":"Cancer"},{"key":"BF02934139_CR133","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1002\/1097-0142(19821001)50:7<1235::AID-CNCR2820500703>3.0.CO;2-L","volume":"50","author":"D Tormey","year":"1982","unstructured":"Tormey D, Gelman R, Band P, Sears M, Rosenthal S, De Wys W, Perlia C, Rice M: Comparison of induction chemotherapies for metastatic breast cancer: an Eastern Cooperative Oncology Group Trial.Cancer\n                           50, 1235 (1982).","journal-title":"Cancer"},{"key":"BF02934139_CR134","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/1097-0142(19830815)52:4<606::AID-CNCR2820520405>3.0.CO;2-S","volume":"52","author":"R Chlebowski","year":"1983","unstructured":"Chlebowski R, Pugh R, Weiner J, Block J, Bateman J: Doxorubicin and CCNU with or without vincristine in patients with advanced refractory breast cancer: a randomized trial.Cancer\n                           52, 606 (1983).","journal-title":"Cancer"},{"key":"BF02934139_CR135","doi-asserted-by":"crossref","first-page":"389","DOI":"10.7326\/0003-4819-84-4-389","volume":"84","author":"G P Canellos","year":"1976","unstructured":"Canellos G P, DeVita V T, Gold G L, Chasner B, Schein P S, Young R C: Combination chemotherapy for advanced breast cancer: Response and effect on survival.Ann Int Med\n                           84, 389 (1976).","journal-title":"Ann Int Med"},{"key":"BF02934139_CR136","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1002\/1097-0142(197504)35:4<1101::AID-CNCR2820350413>3.0.CO;2-M","volume":"35","author":"R Creech","year":"1975","unstructured":"Creech R, Catalano R, Mastrangelo M, Engstrom P: An effective low-dose intermittent cyclophosphamide, methotrexate and 5-fluorouracil treatment regimen for metastatic breast cancer.Cancer\n                           35, 1101 (1975).","journal-title":"Cancer"},{"key":"BF02934139_CR137","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/1097-0142(197507)36:1<90::AID-CNCR2820360104>3.0.CO;2-H","volume":"36","author":"S Jones","year":"1975","unstructured":"Jones S, Dupre B, Salmon S: Combination chemotherapy with adriamycin and cyclophosphamide for advanced breast cancer.Cancer\n                           36, 90 (1975).","journal-title":"Cancer"},{"key":"BF02934139_CR138","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1002\/1097-0142(19820301)49:5<835::AID-CNCR2820490502>3.0.CO;2-Z","volume":"49","author":"B Tranum","year":"1982","unstructured":"Tranum B, McDonald B, Thigpen T, Vaughn C, Wilson H, Maloney T, Costanzi J, Bickers J, el Mawli N, Palmer R, Hoogstraten B, Heilburn L, Rasmussen S: Adriamycin combination in advanced breast cancer: a Southwest Oncology Group Study.Cancer\n                           49, 835 (1982).","journal-title":"Cancer"},{"key":"BF02934139_CR139","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/1097-0142(197901)43:1<60::AID-CNCR2820430108>3.0.CO;2-M","volume":"43","author":"R Lloyd","year":"1979","unstructured":"Lloyd R, Jones S, Salmon S: Comparative trial of low-dose adriamycin plus cyclophosphamide with or without additive hormonal therapy in advanced breast cancer.Cancer\n                           43, 60 (1979).","journal-title":"Cancer"},{"key":"BF02934139_CR140","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1002\/1097-0142(19820515)49:10<1988::AID-CNCR2820491007>3.0.CO;2-L","volume":"49","author":"T Nemoto","year":"1982","unstructured":"Nemoto T, Horton J, Simon R, Dao T, Rosner D, Cunningham R, Sponzo R, Snyderman M: Comparison of four-combination chemotherapy programs in metastatic breast cancer: comparison of multiple drug therapy with cytoxan, 5FU and prednisone versus cytoxan and adriamycin versus cytoxan, 5FU and adriamycin versus cytoxan, 5FU and prednisone alternating with cytoxan and adriamycin.Cancer\n                           49, 1988 (1982).","journal-title":"Cancer"},{"key":"BF02934139_CR141","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1136\/bmj.1.6013.801","volume":"1","author":"C Brambilla","year":"1976","unstructured":"Brambilla C, De Lena M, Rossi A, Valagussa P, Bonadonna G: Response and survival in advanced breast cancer after two non-cross-resistant combinations.Br Med J\n                           1, 801 (1976).","journal-title":"Br Med J"},{"key":"BF02934139_CR142","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1002\/1097-0142(197802)41:2<396::AID-CNCR2820410203>3.0.CO;2-T","volume":"41","author":"J Russell","year":"1978","unstructured":"Russell J, Baker J, Dady P, Ford H, Gazet J, McKinna J, Nash A, Powles T: Combination chemotherapy of metastatic breast cancer with vincristine, adriamycin and prednisolone.Cancer\n                           41, 396 (1978).","journal-title":"Cancer"},{"key":"BF02934139_CR143","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/1097-0142(197901)43:1<66::AID-CNCR2820430109>3.0.CO;2-1","volume":"43","author":"J Rainey","year":"1979","unstructured":"Rainey J, Jones S, Salmon C: Combination chemotherapy for advanced breast cancer utilizing vincristine, adriamycin, and cyclophosphamide (VAC).Cancer\n                           43, 66 (1979).","journal-title":"Cancer"},{"key":"BF02934139_CR144","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1002\/1097-0142(19811001)48:7<1517::AID-CNCR2820480707>3.0.CO;2-8","volume":"48","author":"J Carmo-Pereira","year":"1981","unstructured":"Carmo-Pereira J, Costa F, Henriques E: Chemotherapy of advanced breast cancer: a randomized trial of vincristine, adriamycin, and cyclophosphamide (VAC) versus cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP).Cancer\n                           48, 1517 (1981).","journal-title":"Cancer"},{"key":"BF02934139_CR145","first-page":"193","volume":"10","author":"G Blumenschein","year":"1974","unstructured":"Blumenschein G, Cardenas J, Freireich E, Gottlieb J: FAC chemotherapy for breast cancer.Proc Am Assoc Clin Oncol\n                           10, 193 (1974).","journal-title":"Proc Am Assoc Clin Oncol"},{"key":"BF02934139_CR146","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1002\/1097-0142(197806)41:6<2078::AID-CNCR2820410602>3.0.CO;2-Q","volume":"41","author":"B Tranum","year":"1978","unstructured":"Tranum B, Hoogstraten B, Kennedy A, Vaughan C, Samal B, Thigpen T, Rivkin S, Smith F, Palmer R, Costanzi J, Tucker W, Wilson H, Moloney T: Adriamycin in combination for the treatment of breast cancer: a Southwest Oncology Group Study.Cancer\n                           41, 2078 (1978).","journal-title":"Cancer"},{"key":"BF02934139_CR147","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/1097-0142(197708)40:2<625::AID-CNCR2820400206>3.0.CO;2-M","volume":"40","author":"R Smalley","year":"1977","unstructured":"Smalley R, Carpenter J, Bartolucci A, Vogel C, Krauss S: A comparison of cyclophosphamide, adriamycin, 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer: a Southeastern Cancer Study Group project.Cancer\n                           40, 625 (1977).","journal-title":"Cancer"},{"key":"BF02934139_CR148","first-page":"443","volume":"22","author":"J Aisner","year":"1981","unstructured":"Aisner J, Weinberg V, Perloff M, Weiss R, Raich P, Perry M, Wiernik P: Chemoimmunotherapy for advanced breast cancer: a randomized comparison of 6 combinations (CMF, CAF vs CAFVP) each with or without MER immunotherapy: a CALGB study.Proc ASCO\n                           22, 443 (1981).","journal-title":"Proc ASCO"},{"key":"BF02934139_CR149","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1002\/1097-0142(197812)42:6<2534::AID-CNCR2820420605>3.0.CO;2-P","volume":"32","author":"M Perloff","year":"1978","unstructured":"Perloff M, Hart R, Holland J: Vinblastine, adriamycin, thiotepa, and halotestin (VATH): therapy for advanced breast cancer refractory to prior therapy.Cancer\n                           32, 2534 (1978).","journal-title":"Cancer"},{"key":"BF02934139_CR150","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1002\/1097-0142(19811001)48:7<1522::AID-CNCR2820480709>3.0.CO;2-G","volume":"48","author":"R Hart","year":"1981","unstructured":"Hart R, Perloff M, Holland J: One-day VATH (vinblastine, adriamycin, thiotepa, and halotestin) therapy for advanced breast cancer refractory to chemotherapy.Cancer\n                           48, 1522 (1981).","journal-title":"Cancer"},{"key":"BF02934139_CR151","first-page":"111","volume":"2","author":"H Yap","year":"1983","unstructured":"Yap H, Blumenschein G, Hortobagyi G, Bodey G: Mitoxantrone, cyclophosphamide and 5-fluorouracil in metastatic breast cancer.Proc ASCO\n                           2, 111 (1983).","journal-title":"Proc ASCO"},{"key":"BF02934139_CR152","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/bjc.1975.284","volume":"32","author":"R Rubens","year":"1975","unstructured":"Rubens R, Knight R, Hayward J: Chemotherapy of advanced breast cancer: a controlled randomized trial of cyclophosphamide versus a four-drug combination.Br J Cancer\n                           32, 730 (1975).","journal-title":"Br J Cancer"},{"key":"BF02934139_CR153","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1002\/1097-0142(197611)38:5<1882::AID-CNCR2820380503>3.0.CO;2-H","volume":"38","author":"G Canellos","year":"1976","unstructured":"Canellos G, Pocock S, Taylor S, Sears M, Klaasen D, Bard P: Combination chemotherapy for metastatic breast carcinoma: prospective comparison of multiple drug therapy with L-phenylalanine mustard.Cancer\n                           38, 1882 (1976).","journal-title":"Cancer"},{"key":"BF02934139_CR154","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/1097-0142(197402)33:2<513::AID-CNCR2820330228>3.0.CO;2-H","volume":"33","author":"L Baker","year":"1974","unstructured":"Baker L, Vaughn C, Al-Sarraf M, Reed M, Vaitkevicius V: Evaluation of combination vs sequential cytotoxic chemotherapy in the treatment of advanced breast cancer.Cancer\n                           33, 513 (1974).","journal-title":"Cancer"},{"key":"BF02934139_CR155","first-page":"4503","volume":"39","author":"R Chlebowski","year":"1979","unstructured":"Chlebowski R, Irwin L, Pugh R, Sadoff L, Hestorff R, Wiener J, Bateman J: Survival of patients with metastatic breast cancer treated with either combination or sequential chemotherapy.Cancer Res\n                           39, 4503 (1979).","journal-title":"Cancer Res"},{"key":"BF02934139_CR156","first-page":"1685","volume":"61","author":"M Abeloff","year":"1977","unstructured":"Abeloff M, Ettinger D: Treatment of metastatic breast cancer with adriamycin-cyclophosphamide induction followed by alternating combination therapy.Cancer Treat Rep\n                           61, 1685 (1977).","journal-title":"Cancer Treat Rep"},{"key":"BF02934139_CR157","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00000421-198306010-00001","volume":"6","author":"D Tormey","year":"1983","unstructured":"Tormey D, Gelman R, Falkson G: Prospective evaluation of rotating chemotherapy in advanced breast cancer: an Eastern Cooperative Oncology Group trial.Am J Clin Oncol (CCT)6, 1 (1983).","journal-title":"Am J Clin Oncol (CCT)"},{"key":"BF02934139_CR158","first-page":"2077","volume":"63","author":"C Vogel","year":"1979","unstructured":"Vogel C, Love N, East D, Moore M, Smalley R: Phase II study of alternating cytoreductive and cycle-active combination chemotherapy for metastatic breast cancer.Cancer Treat Rep\n                           63, 2077 (1979).","journal-title":"Cancer Treat Rep"},{"key":"BF02934139_CR159","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1002\/1097-0142(19800215)45:4<742::AID-CNCR2820450422>3.0.CO;2-X","volume":"45","author":"G Blumenschein","year":"1980","unstructured":"Blumenschein G, Hortobagyi G, Richman S, Gutterman J, Tashima C, Buzdar A, Burgess M, Livingston R, Hersh E: Alternating noncross-resistant combination chemotherapy and active nonspecific immunotherapy with BCG or MER-BCG for advanced breast cancer.Cancer\n                           45, 742 (1980).","journal-title":"Cancer"},{"key":"BF02934139_CR160","first-page":"67","volume":"65","author":"I Henderson","year":"1981","unstructured":"Henderson I, Gelman R, Canellos G, Frei E: Prolonged disease-free survival in advanced breast cancer treated with \u201csuper-CMF\u201d adriamycin: an alternating regimen employing high-dose methotrexate with citrovorum factor rescue.Cancer Treat Rep\n                           65 (Suppl.), 67 (1981).","journal-title":"Cancer Treat Rep"},{"key":"BF02934139_CR161","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1126\/science.472732","volume":"205","author":"E Cadman","year":"1979","unstructured":"Cadman E, Heimes R, Davis L: Enhanced 5-fluorouracil nucleotide formation after methotrexate administration: explanation for drug synergism.Science\n                           205 1135 (1979).","journal-title":"Science"},{"key":"BF02934139_CR162","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1002\/1097-0142(19810601)47:11<2552::AID-CNCR2820471106>3.0.CO;2-Y","volume":"47","author":"A Gewirtz","year":"1981","unstructured":"Gewirtz A, Cadman E: Preliminary report on the efficacy of sequential methotrexate and 5-fluorouracil in advanced breast cancer.Cancer\n                           47, 2552 (1981).","journal-title":"Cancer"},{"key":"BF02934139_CR163","first-page":"86","volume":"1","author":"R Herrmann","year":"1982","unstructured":"Herrmann R, Westerhausen M, Bruntsch U, Jungi F, Manegold C, Fritze D: Sequential methotrexate (MTX) and 5-fluorouracil (FU) is effective in extensively pretreated breast cancer.Proc ASCO\n                           1, 86 (1982).","journal-title":"Proc ASCO"},{"key":"BF02934139_CR164","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1002\/1097-0142(197705)39:5<1940::AID-CNCR2820390505>3.0.CO;2-0","volume":"39","author":"R O'Bryan","year":"1977","unstructured":"O'Bryan R, Baker L, Gottlieb E, Rivkin S, Balcerzak S, Grumet G, Salman S, Moon T, Hoogstraten B: Dose response evaluation of adriamycin in human neoplasia.Cancer\n                           39, 1940 (1977).","journal-title":"Cancer"},{"key":"BF02934139_CR165","first-page":"100","volume":"2","author":"D Perrault","year":"1983","unstructured":"Perrault D, Erlichman C, Hasselback R, Tannock I, Boyd N: Sequenced methotrexate (MTX) and 5-fluorouracil (5FU) in refractory metastatic breast cancer: a Phase II study.Proc ASCO\n                           2, 100 (1983).","journal-title":"Proc ASCO"},{"key":"BF02934139_CR166","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1002\/1097-0142(197706)39:6<2923::AID-CNCR2820390679>3.0.CO;2-3","volume":"39","author":"K Brunner","year":"1977","unstructured":"Brunner K, Sonntag R, Alberto P, Senn H, Martz G, Obrecht P, Maurice P: Combined chemo-and hormonal therapy in advanced breast cancer.Cancer\n                           39, 2923 (1977).","journal-title":"Cancer"},{"key":"BF02934139_CR167","unstructured":"Kardinal C: Personal communication (1983)."},{"key":"BF02934139_CR168","first-page":"106","volume":"2","author":"J Krook","year":"1983","unstructured":"Krook J, Ingle J, Green S, Bowman W, Duluth M: Randomized trial of cyclophosphamide, 5-fluorouracil, prednisone (CFP) plus or minus tamoxifen (T) in postmenopausal women with advanced breast cancer.Proc ASCO\n                           2, 106 (1983).","journal-title":"Proc ASCO"},{"key":"BF02934139_CR169","first-page":"75","volume":"18","author":"G Cocconi","year":"1982","unstructured":"Cocconi G, De Lisi V, Boni C, Mori P: CMF vs CMV plus tamoxifen (T) in postmenopausal metastatic breast cancer: a prospective randomized study.Proc ASCO\n                           18, 75 (1982).","journal-title":"Proc ASCO"},{"key":"BF02934139_CR170","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1002\/1097-0142(197906)43:6<2215::AID-CNCR2820430609>3.0.CO;2-3","volume":"43","author":"G Falkson","year":"1979","unstructured":"Falkson G, Falkson H, Glidewell O, Weinberg V, Leone L, Holland J F: Improved remission rates and remission duration in young women with metastatic breast cancer following combined oophorectomy and chemotherapy: a study by the Cancer and Leukemia Group B.Cancer\n                           43, 2215 (1979).","journal-title":"Cancer"},{"key":"BF02934139_CR171","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1056\/NEJM197708182970704","volume":"297","author":"D Ahmann","year":"1977","unstructured":"Ahmann D, O'Conell M, Hahn R, Bisel H, Lee R, Edmonson J: An evaluation of early or delayed adjuvant chemotherapy in premenopausal patients with advanced breast cancer undergoing oophorectomy.New Engl J Med\n                           297, 356 (1977).","journal-title":"New Engl J Med"},{"key":"BF02934139_CR172","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/00000421-198208000-00003","volume":"5","author":"D Ahmann","year":"1982","unstructured":"Ahmann D, Green S, Bisel H, Ingle J: An evaluation of early or delayed adjuvant chemotherapy in premenopausal patients with advanced breast cancer undergoing oophorectomy: a later analysis.Am J Clin Oncol (CCT)5, 355 (1982).","journal-title":"Am J Clin Oncol (CCT)"},{"key":"BF02934139_CR173","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1002\/1097-0142(19800215)45:4<735::AID-CNCR2820450421>3.0.CO;2-S","volume":"45","author":"J Glick","year":"1980","unstructured":"Glick J, Creech R, Torri S, Holroyde C, Brodovsky H, Catalano R, Varano M: Tamoxifen plus sequential CMF chemotherapy versus tamoxifen alone in postmenopausal patients with advanced breast cancer: a randomized trial.Cancer\n                           45, 735 (1980).","journal-title":"Cancer"},{"key":"BF02934139_CR174","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1002\/1097-0142(19821215)50:12<2747::AID-CNCR2820501209>3.0.CO;2-Y","volume":"50","author":"W Bezwoda","year":"1982","unstructured":"Bezwoda W, Derman D, Moor N, Lange M, Levin J: Treatment of metastatic breast cancer in estrogen receptor positive patients: a randomized trial comparing tamoxifen alone versus tamoxifen plus CMF.Cancer\n                           50, 2747 (1982).","journal-title":"Cancer"},{"key":"BF02934139_CR175","first-page":"441","volume":"22","author":"J Allegra","year":"1981","unstructured":"Allegra J, Woodcock T, Richman S, Patel J, Wittliff J: A Phase II evaluation of tamoxifen, premarin, methotrexate (MTX) and 5-fluorouracil (5FU) in stage IV breast cancer.Proc ASCO 22, 441 (1981).","journal-title":"Proc ASCO"},{"key":"BF02934139_CR176","first-page":"79","volume":"1","author":"M Lippman","year":"1982","unstructured":"Lippman M, Cassidy J, Wesley M, Young R: A randomized attempt to increase the efficacy of cytotoxic chemotherapy in metastatic breast cancer by hormonal synchronization.Proc ASCO\n                           1, 79 (1982).","journal-title":"Proc ASCO"},{"key":"BF02934139_CR177","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1002\/1097-0142(197911)44:5<1955::AID-CNCR2820440559>3.0.CO;2-P","volume":"44","author":"G Hortobagyi","year":"1979","unstructured":"Hortobagyi G, Gutterman J, Blumenschein G, Tashima C, Burgess M, Einhorn L, Buzdar A, Richman P, Hersh F: Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide and BCGCancer\n                           44, 1955 (1979).","journal-title":"Cancer"},{"key":"BF02934139_CR178","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1002\/1097-0142(19810501)47:9<2295::AID-CNCR2820470932>3.0.CO;2-8","volume":"47","author":"H Muss","year":"1981","unstructured":"Muss H, Richards F, Cooper R, White D, Jackson D, Howard V, Shore A, Rhyne A, Spurr C: Chemotherapy vs chemoimmunotherapy with methanol extraction residue of Bacillus Calmette-Guerin (MER) in advanced breast cancer: a randomized trial by the Piedmont Oncology Association.Cancer\n                           47, 2295 (1981).","journal-title":"Cancer"},{"key":"BF02934139_CR179","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/1097-0142(197903)43:3<1112::AID-CNCR2820430350>3.0.CO;2-M","volume":"43","author":"G Hortobagyi","year":"1979","unstructured":"Hortobagyi G, Gutterman J, Blumenschein G, Yap H, Buzdar A, Tashima C, Burgess M, Hersh E: Combined chemoimmunotherapy for advanced breast cancer: a comparison of BCG and levamisole.Cancer\n                           43, 1112 (1979).","journal-title":"Cancer"},{"key":"BF02934139_CR180","first-page":"65","volume":"64","author":"P Klefstrom","year":"1980","unstructured":"Klefstrom P: Combination of levamisole immunotherapy and polychemotherapy in advanced breast cancer.Cancer Treat Rep\n                           64, 65 (1980).","journal-title":"Cancer Treat Rep"},{"key":"BF02934139_CR181","first-page":"79","volume":"131","author":"B Fisher","year":"1970","unstructured":"Fisher B, Slack N: Number of lymph nodes examined and the prognosis in breast cancer.Surg Gynec Obst\n                           131, 79 (1970).","journal-title":"Surg Gynec Obst"},{"key":"BF02934139_CR182","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1002\/1097-0142(19821215)50:12<2884::AID-CNCR2820501231>3.0.CO;2-K","volume":"50","author":"B Stenkvist","year":"1982","unstructured":"Stenkvist B, Bengtsson E, Dahlquist B, Eklund G, Eriksson O, Jarkrans T, Nordin B: Predicting breast cancer recurrence.Cancer\n                           50, 2884 (1982).","journal-title":"Cancer"},{"key":"BF02934139_CR183","first-page":"144","volume":"23","author":"J Hager","year":"1982","unstructured":"Hager J, Furmanski P, Heppner G, Roi L, Brennan M, Rich M: Breast Cancer Prognostic Study Association: correlation between elevated preoperative CEA levels and early recurrence in breast cancer patients.Proc AACR\n                           23, 144 (1982).","journal-title":"Proc AACR"},{"key":"BF02934139_CR184","first-page":"155","volume":"21","author":"R Weigand","year":"1980","unstructured":"Weigand R, Isenberg W, Russo J, Rich M: Breast Cancer Prognostic Study Association: blood vessel invasion as a prognostic indicator in human breast cancers.Proc AACR\n                           21, 155 (1980).","journal-title":"Proc AACR"},{"key":"BF02934139_CR185","first-page":"543","volume":"100","author":"M Black","year":"1955","unstructured":"Black M, Speer F: Survival in breast cancer cases in relation to the structure of the primary tumor and regional lymph nodes.Surg Gynec Obst\n                           100, 543 (1955).","journal-title":"Surg Gynec Obst"},{"key":"BF02934139_CR186","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1002\/1097-0142(19810515)47:10<2364::AID-CNCR2820471007>3.0.CO;2-S","volume":"47","author":"D Kinne","year":"1981","unstructured":"Kinne D, Ashikari R, Butler A, Menendez-Botet C, Rosen P, Schwartz M: Estrogen receptor-protein in breast cancer as a predictor of recurrence.Cancer\n                           47, 2364 (1981).","journal-title":"Cancer"},{"key":"BF02934139_CR187","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1002\/1097-0142(19801215)46:12+<2765::AID-CNCR2820461404>3.0.CO;2-C","volume":"46","author":"R Blamey","year":"1980","unstructured":"Blamey R, Bishop H, Blake J, Doyle P, Elston C, Haybittle J, Nicholson R, Griffiths K: Relationship between primary breast tumor receptor status and patient survival.Cancer\n                           46, 2765 (1980).","journal-title":"Cancer"},{"key":"BF02934139_CR188","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/bjc.1981.9","volume":"43","author":"R Leake","year":"1981","unstructured":"Leake R, Laing L, McArdle C, Smith D: Soluble and nuclear oestrogen receptor status in human breast cancer in relation to prognosis.Br J Cancer\n                           43, 67 (1981).","journal-title":"Br J Cancer"},{"key":"BF02934139_CR189","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1002\/1097-0142(19800415)45:8<1993::AID-CNCR2820450802>3.0.CO;2-2","volume":"45","author":"R Hilf","year":"1980","unstructured":"Hilf R, Feldstein M, Gibson S, Savlov E: The relative importance of estrogen receptor analysis as a prognostic factor for recurrence or response to chemotherapy in women with breast cancer.Cancer\n                           45, 1993 (1980).","journal-title":"Cancer"},{"key":"BF02934139_CR190","unstructured":"Gallagher H: Current controversies in breast cancer, presented at M. D. Anderson, 3\u20135 November (1982)."},{"key":"BF02934139_CR191","first-page":"142","volume-title":"Recent Results in Cancer Research. Adjuvant Therapies of Cancer","author":"R Nissen-Meyer","year":"1982","unstructured":"Nissen-Meyer R, Kjellgren K, Mansson B: Adjuvant chemotherapy in breast cancer, in Math\u00e9 G, Bonadonna G, Salmon S (eds)Recent Results in Cancer Research. Adjuvant Therapies of Cancer,pp. 142\u2013148. Berlin, Springer. (1982)."},{"key":"BF02934139_CR192","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1002\/1097-0142(19800815)46:4+<1009::AID-CNCR2820461326>3.0.CO;2-H","volume":"46","author":"B Fisher","year":"1980","unstructured":"Fisher B, Redmond C, Fisher E: The contribution at recent NSABP clinical trials of primary breast cancer therapy to an understanding of tumor biology\u2014an overview of findings.Cancer\n                           46, 1009 (1980).","journal-title":"Cancer"},{"key":"BF02934139_CR193","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(83)91385-5","volume":"i","author":"R Rubens","year":"1983","unstructured":"Rubens R, Knight R, Fentiman I, Howell A, Crowther D, George W, Hayward J, Balbrook R, Chandary M, Bush H, Sellwood R, Howat J: Controlled trial of adjuvant chemotherapy with melphalan for breast cancer.Lancet\n                           i, 839 (1983).","journal-title":"Lancet"},{"key":"BF02934139_CR194","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1056\/NEJM197602192940801","volume":"294","author":"G Bonadonna","year":"1976","unstructured":"Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brambilla C, De Lena M, Tancini G, Bajetta E, Musumeci R, Veronesi U: Combination chemotherapy as an adjuvant treatment in operable breast cancer.New Engl J Med\n                           294, 405 (1976).","journal-title":"New Engl J Med"},{"key":"BF02934139_CR195","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1136\/bmj.282.6274.1427","volume":"282","author":"A Rossi","year":"1981","unstructured":"Rossi A, Bonadonna G, Valagussa P, Veronesi U: Multimodal treatment in operable breast cancer: five-year results of the CMF programme.Br Med J\n                           282, 1427 (1981).","journal-title":"Br Med J"},{"key":"BF02934139_CR196","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1056\/NEJM198101013040103","volume":"304","author":"G Bonadonna","year":"1981","unstructured":"Bonadonna G, Valagussi P: Dose-response effect of adjuvant chemotherapy in breast cancer.New Engl J Med\n                           304, 10 (1981).","journal-title":"New Engl J Med"},{"key":"BF02934139_CR197","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1200\/JCO.1983.1.1.2","volume":"1","author":"G Tancini","year":"1983","unstructured":"Tancini G, Bonadonna G, Valagussa P, Marchini S, Veronesi U: Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles.J Clin Oncol\n                           1, 2 (1983).","journal-title":"J Clin Oncol"},{"key":"BF02934139_CR198","first-page":"80","volume":"18","author":"E Velez-Garcia","year":"1982","unstructured":"Velez-Garcia E, Moore M, Marcial V, Bartolucci A, Ketcham A, Smalley R: Adjuvant chemotherapy and radiotherapy in Stage II breast cancer.Proc ASCO\n                           18, 80 (1982).","journal-title":"Proc ASCO"},{"key":"BF02934139_CR199","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1002\/1097-0142(197909)44:3<793::AID-CNCR2820440302>3.0.CO;2-Y","volume":"44","author":"R Cooper","year":"1979","unstructured":"Cooper R, Holland J, Glidewell O: Adjuvant chemotherapy of breast cancer.Cancer\n                           44, 793 (1979).","journal-title":"Cancer"},{"key":"BF02934139_CR200","first-page":"817","volume":"150","author":"J Holland","year":"1980","unstructured":"Holland J, Glidewell O, Cooper R: Adverse effect of radiotherapy on adjuvant chemotherapy for carcinoma of the breast.Surg Gynec Obst\n                           150, 817 (1980).","journal-title":"Surg Gynec Obst"},{"key":"BF02934139_CR201","first-page":"377","volume-title":"Adjuvant Therapy of Cancer","author":"D Tormey","year":"1981","unstructured":"Tormey D, Holland J, Weinberg V, Weiss R, Falkson G, Glidewell O, Leone L, Perloff M: 5-drug vs 3-dru \u00b1 MER postoperative chemotherapy for mammary carcinoma, inAdjuvant Therapy of Cancer, Salmon S. and Jones S. (eds), vol. III, pp. 377\u2013384. New York, Grune & Stratton (1981)."},{"key":"BF02934139_CR202","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1002\/1097-0142(19820801)50:3<423::AID-CNCR2820500307>3.0.CO;2-O","volume":"50","author":"H Glucksberg","year":"1982","unstructured":"Glucksberg H, Rivkin S, Rasmussen S, Tranum B, Gad-el-Mawla N, Costanzi J, Hoogstraten B, Athens J, Maloney T, McCracken J, Vaughn C: Combination chemotherapy (CMFVP) versus L-phenylalanine mustard (L-PAM) for operable breast cancer with positive axillary nodes. A Southwest Oncology Group Study.Cancer\n                           50, 423\u2013434 (1982).","journal-title":"Cancer"},{"key":"BF02934139_CR203","first-page":"100","volume":"2","author":"S Rivkin","year":"1983","unstructured":"Rivkin S, Glucksberg H, Foulkes M: Adjuvant chemotherapy for operable breast cancer with positive axillary nodes.Proc ASCO\n                           2, 100 (1983).","journal-title":"Proc ASCO"},{"key":"BF02934139_CR204","first-page":"453","volume-title":"Adjuvant Therapy of Cancer","author":"H Allen","year":"1981","unstructured":"Allen H, Brooks R, Jones S, Chase E, Heuskinkveld R, Giordano G, Ketchel S, Jackson R, Davis S, Moon T, Salmon S: Adjuvant treatment for Stage II (node-positive) breast cancer with adriamycin, cyclophosphamide (AC) \u00b1 radiotherapy (XRT), in Salmon S and Jones S (eds)Adjuvant Therapy of Cancer, vol. III, pp. 453\u2013462. New York, Grune & Stratton (1981)."},{"key":"BF02934139_CR205","first-page":"85","volume":"1","author":"R Brooks","year":"1982","unstructured":"Brooks R, Jones S, Salmon S, Chase E, Davis S, Moon T, Giordano G, Ketchel S: Doxorubicin and cyclophosphamide adjuvant therapy of node negative breast cancer.Proc ASCO\n                           1, 85 (1982).","journal-title":"Proc ASCO"},{"key":"BF02934139_CR206","first-page":"77","volume":"1","author":"M Ali","year":"1982","unstructured":"Ali M, Cheng R, Buzdar A, Ewer M, Haynie T: Non-invasive cardiac studies before and after adriamycin containing chemotherapy (FAC) for stages II and III breast cancer.Proc ASCO\n                           1, 77 (1982).","journal-title":"Proc ASCO"},{"key":"BF02934139_CR207","first-page":"84","volume":"1","author":"J Misset","year":"1982","unstructured":"Misset J, Delgado M, Plagne R, Belpomme D, Guerrin J, Fumoleau P, Metz R, Math\u00e9 G: Three year results of a randomized trial comparing CMF to adriamycin (ADM), vincristine (VCR), cyclophosphamide (CPM) and 5-fluorouracil (5-FU) (ACVF) as adjuvant therapy for operated N+breast cancer.Proc ASCO\n                           1, 84 (1982).","journal-title":"Proc ASCO"},{"key":"BF02934139_CR208","first-page":"142","volume":"23","author":"A Buzdar","year":"1982","unstructured":"Buzdar A, Blumenschein G, Smith T, Powell K, Hortobagyi G, Yap H, Hersh E: Adjuvant chemotherapy for breast cancer with fluorouracil, adriamycin, cyclophosphamide (FAC) with or without BCG and with or without postoperative radiation (XRT): a prospective randomized study.Proc AACR\n                           23, 142 (1982).","journal-title":"Proc AACR"},{"key":"BF02934139_CR209","first-page":"1055","volume":"131","author":"R Ravdin","year":"1970","unstructured":"Ravdin R, Lewison E, Slack N, Dao T, Gardner B, State D, Fisher B: Results of a clinical trial concerning the worth of prophylactic oophorectomy for breast carcinoma.Surg Gynec Obst\n                           131, 1055 (1970).","journal-title":"Surg Gynec Obst"},{"key":"BF02934139_CR210","first-page":"183","volume":"Suppl 1","author":"T Palshof","year":"1980","unstructured":"Palshof T, Mouridsen H, Daehnfeldt S: Adjuvant endocrine therapy of primary operable breast cancer. Report on the Copenhagen Breast Cancer Trials.Eur J Cancer (Suppl 1) 183 (1980).","journal-title":"Eur J Cancer"},{"key":"BF02934139_CR211","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM198107023050101","volume":"305","author":"B Fisher","year":"1981","unstructured":"Fisher B, Redmond C, Brown A, Wolmark Net al: Treatment of primary breast cancer with chemotherapy and tamoxifen.New Engl J Med\n                           305, 1 (1981).","journal-title":"New Engl J Med"},{"key":"BF02934139_CR212","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1002\/1097-0142(19801215)46:12+<2805::AID-CNCR2820461413>3.0.CO;2-H","volume":"46","author":"C Hubay","year":"1980","unstructured":"Hubay C, Pearson O, Marshall J, Rhodes R, De Banne R, Rosenblatt J, Mangone E, Hermann R, Jones J, Flynn W, Eckert C, McGuire W: Adjuvant chemotherapy for Stage II breast cancer: 45-month follow-up of a prospective, randomized clinical trial.Cancer\n                           46, 2805 (1980).","journal-title":"Cancer"},{"key":"BF02934139_CR213","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1002\/1097-0142(19800415)45:8<2042::AID-CNCR2820450809>3.0.CO;2-F","volume":"45","author":"C Kardinal","year":"1980","unstructured":"Kardinal C, Donegan W: Second cancers after prolonged adjuvant thiotepa for operable carcinoma of the breast.Cancer\n                           45, 2042 (1980).","journal-title":"Cancer"},{"key":"BF02934139_CR214","first-page":"269","volume":"64","author":"A Wendt","year":"1980","unstructured":"Wendt A, Jones S, Salmon S: Salvage treatment of patients relapsing after breast cancer adjuvant chemotherapy.Cancer Treat Rep\n                           64, 269 (1980).","journal-title":"Cancer Treat Rep"}],"container-title":["Medical Oncology and Tumor Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02934139.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/BF02934139\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02934139.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T18:42:53Z","timestamp":1631904173000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/BF02934139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1984,9]]},"references-count":214,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1984,9]]}},"alternative-id":["BF02934139"],"URL":"https:\/\/doi.org\/10.1007\/bf02934139","relation":{},"ISSN":["0736-0118"],"issn-type":[{"value":"0736-0118","type":"print"}],"subject":[],"published":{"date-parts":[[1984,9]]}}}